Obermatt
See Similar Stocks →

Assertio Therapeutics

NAQ:ASRT · US04546C3043
PharmaceuticalsSmall

360

34
Medium confidence — indicative
Profit price—
Owner Earnings Yield80
Dividend Yield1
Price/Sales90
EV / Gross Profit73
Price/Book60
Return on Capital32
Return on Equity27
EBIT Margin12
Gross Profitability79

Cash truth not applicable for financial companies.

Sales growth20
Profit growth58
Reinvestment42
Price momentum86
Debt load37
Debt serviceability90
Liquidity39
Analyst ratings12
Opinion Changes50
Price Target Upside1
Market mood1
Value Creation3/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Assertio Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2020
Employees59
Websiteassertiotx.com
ISINUS04546C3043
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyChronic DiseasesPain ManagementRheumatologyOncologyBiotechnologyHealth CareHealth DiagnosticsLife ScienceMedicalPharmaceutical

Description

Assertio Holdings, Inc. (Assertio) operates as a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. The company focuses on supporting patients by marketing products…

Analysis

Middle-of-the-road

Assertio Holdings, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is uncertain. The company scores 3/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
60
2023202420252026

All-time high

93

Jul 2023

All-time low

7

Jan 2023

Average rank

62

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
90
89
86
88
Price/Earnings
100
96
100
82
Price/Book
60
73
71
70
Dividend Yield
1
1
1
1
Value (overall)
100
72
73
73

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Assertio Therapeutics with its peers
Milestone Pharmaceuticals
NSQ:MIST
4
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Phathom Pharmaceuticals
NSQ:PHAT
37
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Insmed
NSQ:INSM
51
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Grace Therapeutics
NAQ:GRCE
52
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cumberland Pharmaceuticals
NSQ:CPIX
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →